James Hassard - 22 Jun 2021 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Reporting relationship: Chief Commercial Officer
Issuer ticker: ARWR
Reported as of: 22 Jun 2021
Net transaction value: -$323,422
SEC form: 4
Accepted by SEC: 24 Jun 2021, 18:44:06 UTC
Next SEC filing: 09 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/James Hassard

Key filing fact

James Hassard filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 24 Jun 2021.

Key facts

This page summarizes James Hassard's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Jun 2021, 18:44.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$323,422.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARWR transaction

Common Stock

Sale

Transaction value: $323,422
Shares: -3,625
Change %: -3.3%
Price: $89.22
Shares after: 105,750
Date: 22 Jun 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.